An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Highly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Insulet Corporation (NASDAQ: PODD) presented new real-world evidence for its Omnipod 5 Automated Insulin Delivery System at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from February 22-25, 2023, in Berlin. The data showcased the device's effectiveness across various demographics, demonstrating strong glycemic control with minimal low glucose incidents. Omnipod 5, which has been available in the U.S. since August 2022, is set to launch in the UK mid-year and Germany later this year. Insulet plans to discuss future clinical trials and innovations at the symposium.
Positive
Real-world evidence indicates strong glycemic control with Omnipod 5, showing minimal time below target ranges.
Omnipod 5 is set to launch in the UK and Germany, expanding market reach.
Data presented at a major conference could enhance credibility and visibility of Omnipod 5.
Negative
None.
ACTON, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the presentation of new real-world evidence related to the Omnipod® 5 Automated Insulin Delivery System at the 16thInternational Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place February 22 – 25, 2023 in Berlin, Germany, and online.
The first release of Omnipod 5 real-world data will be presented at Insulet’s symposium1, “Innovating Today for a Better Tomorrow: How Omnipod 5 Automated Insulin Delivery System is Changing Diabetes Care.” The Insulet-sponsored symposium will take place on Wednesday, February 22, from 4:15 to 5:45 p.m. CET.
“This dataset is the first preview of how Omnipod 5 is being used across a variety of age groups and other demographics throughout our customer base, which is incredibly exciting,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director. “It tells the story of how this system is impacting our users’ daily management of type 1 diabetes, and we can’t wait to share our insights at ATTD.”
“This Omnipod 5 real-world dataset is striking in that it includes all users, since everyone is connected to the cloud-based system,” said Cari Berget MPH, RN, CDCES, Instructor, University of Colorado School of Medicine, who will discuss the data as part of her symposium presentation. “With this large sample and limited selection bias, we see strong time in target range and minimal time below range, exceeding glycemic targets on average. This is extremely promising for long-term benefit in the real world with this device.”
The symposium, chaired by Dr. Emma Wilmot MB ChB, PhD, Associate Professor, University of Nottingham, will explore the role of the healthcare provider in removing barriers to pump adoption and will provide best practices for optimizing care with Omnipod 5. Dr. Ly will also present plans for future clinical trials and innovations at Insulet.
Omnipod 5 received CE Mark under the Medical Device Regulation (MDR) in September 2022 and has been fully available in the United States since August 2022. The Company plans to launch Omnipod 5 to customers in the United Kingdom mid-year and Germany toward the end of this year.
Clinical Research Presentations at ATTD
A recent investigator-initiated feasibility study evaluated the use of automated insulin delivery (AID) with remote glucose monitoring in a hospital setting. The study was conceived of and conducted by investigators at Emory University, Stanford School of Medicine, and UVA Health.
Dr. Michael Hughes, Instructor at Stanford School of Medicine (Stanford School of Medicine served as a participating clinical trial site for the study led by Emory University), will present the results at ATTD.
“Using automated insulin delivery in the hospital produced encouraging results across a heterogenous group of patients, including both type 1 and type 2 diabetes, steroid use, and a range of admission diagnoses,” said Dr. Hughes. “This is an important step forward for inpatient diabetes management. We hope these data can help us move further toward development of inpatient-specific features, algorithms, and systems.”
In addition, Insulet will present new Omnipod 5 data on the optimization of insulin to carbohydrate ratio settings during the three-month pivotal studies for children and adults with type 1 diabetes. There will also be additional research presented on Insulet’s Omnipod DASH® and Omnipod® Insulin Management System.
Schedule of Oral Presentations
Saturday, February 25, 11:30 a.m. – 1:00 p.m. CET Session 8, Hall M1
Who are the Insulin-Using Adults with Type 2 Diabetes Opting to Initiate Pump Therapy? with Dr. Emily Soriano
Saturday, February 25, 1:45 – 2:45 p.m. CET Session 10, Hall M1
Automated Insulin Delivery for Inpatients with Dysglycemia (AIDING) Feasibility Study with Dr. Michael Hughes
Schedule of e-Poster Presentations
e-Poster EP074 - Setting up for Success: Data-Driven Insights for Determining Insulin to Carbohydrate Ratios with the Omnipod® 5 Automated Insulin Delivery System with Dr. Laya Ekhlaspour
e-Poster EP259 - Omnipod DASH®Association of British Clinical Diabetologists (ABCD) Audit: An Interim Report of Users’ Baseline Characteristics with Dr. Thomas Crabtree
e-Poster EP270 - Improved Glycaemic Control in Children and Young Adults with Type 1 Diabetes Using Tubeless Insulin Pumps vs Multiple Daily Injections in Combination with Glucose Sensors with Dr. Stefanie Lanzinger
e-Poster EP265 - Care Efficiencies with Tubeless vs Tubed Pumps: A Time-and-Motion Study of New Insulin Pump Users with Pete Jennings
e-Poster EP266 - Training New Users with Tubeless and Tubed Insulin Pumps: A Survey of Nurse Experiences with Colin Hopley
e-Poster presentations will be available throughout the entire conference.
The Omnipod booth will be open throughout the conference and the team will be available to discuss Omnipod products with healthcare providers and other ATTD registrants.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 24, 2022 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
What new data did Insulet present at the ATTD 2023 regarding PODD?
Insulet presented new real-world evidence indicating the effectiveness of the Omnipod 5 in managing diabetes, highlighting strong glycemic control and low incidents of hypoglycemia.
When and where is the Omnipod 5 symposium being held?
The Omnipod 5 symposium is scheduled for February 22, 2023, during the ATTD conference in Berlin.
What markets is Insulet planning to expand into with PODD products?
Insulet plans to launch Omnipod 5 in the UK mid-year and in Germany toward the end of 2023.
What are some findings from the Omnipod 5 real-world data?
The findings suggest strong time in target range for users and minimal incidents of being below the target range.
